These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18034623)

  • 1. Pharmacogenetics of the PPAR genes and cardiovascular disease.
    Cresci S
    Pharmacogenomics; 2007 Nov; 8(11):1581-95. PubMed ID: 18034623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics.
    Cresci S
    Expert Opin Pharmacother; 2005 Dec; 6(15):2577-91. PubMed ID: 16316298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARs: therapeutic targets for metabolic disease.
    Berger JP; Akiyama TE; Meinke PT
    Trends Pharmacol Sci; 2005 May; 26(5):244-51. PubMed ID: 15860371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy.
    Lee TI; Kao YH; Chen YC; Huang JH; Hsiao FC; Chen YJ
    Diabetes Res Clin Pract; 2013 Jun; 100(3):330-9. PubMed ID: 23369225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARs at the crossroads of lipid signaling and inflammation.
    Wahli W; Michalik L
    Trends Endocrinol Metab; 2012 Jul; 23(7):351-63. PubMed ID: 22704720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?
    Denning GM; Stoll LL
    Pediatr Pulmonol; 2006 Jan; 41(1):23-34. PubMed ID: 16267824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARs and Myocardial Infarction.
    Wagner KD; Wagner N
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J
    J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G; Staels B
    Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2005 Apr; 5(2):177-83. PubMed ID: 15780828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
    Cheang WS; Tian XY; Wong WT; Huang Y
    Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.
    Laganà AS; Vitale SG; Nigro A; Sofo V; Salmeri FM; Rossetti P; Rapisarda AM; La Vignera S; Condorelli RA; Rizzo G; Buscema M
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure.
    Mistry NF; Cresci S
    Heart Fail Rev; 2010 May; 15(3):197-207. PubMed ID: 18998207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.